A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

NCT03600883 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

713

Enrollment

INDUSTRY

Sponsor class

Conditions

KRAS p.G12C Mutant Advanced Solid Tumors

Interventions

DRUG: sotorasib
DRUG: Anti PD-1/L1
DRUG: Midazolam

Sponsor

Amgen